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Abstract Multiple sclerosis (MS) is an autoimmune, inflam-
matory disease of the central nervous system (CNS). We have
measured the levels of over 20 non-esterified sterols in plasma
and cerebrospinal fluid (CSF) from patients suffering from
MS, inflammatory CNS disease, neurodegenerative disease
and control patients. Analysis was performed following
enzyme-assisted derivatisation by liquid chromatography–
mass spectrometry (LC–MS) exploiting multistage fragmen-
tation (MSn). We found increased concentrations of bile acid
precursors in CSF from each of the disease states and that
patients with inflammatory CNS disease classified as
suspected autoimmune disease or of unknown aetiology also
showed elevated concentrations of 25-hydroxycholestertol
(25-HC, P < 0.05) in CSF. Cholesterol concentrations in
CSF were not changed except for patients diagnosed with
amyotrophic lateral sclerosis (P < 0.01) or pathogen-based
infections of the CNS (P < 0.05) where they were elevated.
In plasma, we found that 25-HC (P < 0.01), (25R)26-
hydroxycholesterol ((25R)26-HC, P < 0.05) and 7α-hy-
droxy-3-oxocholest-4-enoic acid (7αH,3O-CA, P < 0.05)
were reduced in relapsing-remitting MS (RRMS) patients
compared to controls. The pattern of reduced plasma levels
of 25-HC, (25R)26-HC and 7αH,3O-CA was unique to
RRMS. In summary, in plasma, we find that the concentration
of 25-HC in RRMS patients is significantly lower than in
controls. This is consistent with the hypothesis that a lower
propensity of macrophages to synthesise 25-HC will result in
reduced negative feedback by 25-HC on IL-1 family cytokine
production and exacerbated MS. In CSF, we find that the
dominating metabolites reflect the acidic pathway of bile acid
biosynthesis and the elevated levels of these in CNS disease is
likely to reflect cholesterol release as a result of demyelination
or neuronal death. 25-HC is elevated in patients with inflam-
matory CNS disease probably as a consequence of up-
regulation of the type 1 interferon-stimulated gene cholesterol
25-hydroxylase in macrophages.
Keywords Sterol . Oxysterol . Bile acid . CNS .
Inflammation . HPLC .MS
Introduction
Multiple sclerosis (MS) is an autoimmune inflammatory dis-
ease of the central nervous system (CNS). A large number of
genetic variants, together with several putative environmen-
tal agents, including serum vitamins D levels, Epstein–Barr
virus infection and a history of smoking, determine MS sus-
ceptibility [1, 2]. The disease in most cases follows a relaps-
ing–remitting (RR) course where acute autoimmune attacks
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against the CNS are followed by recovery. Many patients
with RRMS go on to develop secondary progressive MS,
characterised by irreversible neurological disability.
Immunological and pathological studies have provided evi-
dence supporting an important role played by the immune
system in driving the abnormal demyelinating process seen
in MS patients [3, 4]. Neuronal degeneration is also a key in
MS pathogenesis and is present already in early disease
stages and is especially evident in the progressive phase of
the disease, when brain atrophy and irreversible disability
are more prominent [4, 5]. Type 1 interferon (IFN) is used
in the treatment of MS, it has a suppressive effect on immu-
nity [6]. IFN-stimulated genes include cholesterol 25-
hydroxylase (CH25H) which is up-regulated in macrophages
upon bacterial or virus infection [7–10]. Recently, several
disease-modifying drugs (DMDs) in addition to the first gen-
eration of injectable DMDs (IFN and glatiramer acetate)
have been developed and licensed. These include
natalizumab, fingolimod, dimethyl fumarate, teriflunomide
and alemtuzumab.
Perturbation of sterol and cholesterol pathways has recent-
ly been linked to various immune disorders [11, 12].
Oxysterols, oxidised metabolites of cholesterol or its precur-
sors, are key mediators of these pathways. As well as being
essential metabolites controlling cholesterol levels and lead-
ing to the production of bile acids, oxysterols have been
shown to modulate the immune system. They, and their
downstream metabolites, are ligands for nuclear hormone re-
ceptors such as the liver X receptors (LXRs), the farnesoid X
receptor, the pregnane X receptor, the RAR-related orphan
receptor γt (RORc2) [13–16], they modulate transcription
in macrophages [17], and RORc2 activation plays a central
role in the differentiation of Th17 cells [18]. Furthermore,
oxysterols can activate a G protein-coupled receptor called
Epstein–Barr virus-induced gene 2 (EBI2, GPR183) and
oxysterol gradients guide migration of EBI2 expressing im-
mune cells [19, 20], many of which have been implicated in
shaping the adapted and innate immune response. We
hypothesised that oxysterol concentrations vary under patho-
physiological conditions and set out to determine using liquid
chromatography–mass spectrometry (LC–MS) oxysterol
levels in plasma and cerebrospinal fluid (CSF) from patients
suffering from MS, both RRMS and clinically isolated syn-
drome (CIS), and from symptomatic control patients (CP).
Note, we use italics to differentiate the abbreviation for mass
spectrometry (MS), from that for multiple sclerosis (MS). In
addition, samples from patients with neurodegenerative dis-
ease i.e. Alzheimer’s disease (AD) or Parkinson’s disease
(PD), amyotrophic lateral sclerosis (ALS), and inflammatory
CNS disease i.e. suspected autoimmune disease or of un-
known aetiology (SA/UA) and pathogen-based infection
(PBI), were analysed. The CSF data for the CP group has
been published elsewhere [21].
Materials and Methods
Patients and Controls
Written informed consent was obtained from all patients in
accordance with the Declaration of Helsinki, and the study
was approved by the Common Institutional Review Board
of the Cantons of Basel, Switzerland.
Samples were stratified into the following groups: (1) CIS,
(n = 16); (2) RRMS, (n = 17); (3) CP (n = 18), i.e. patients with
neurological symptoms, but no objective clinical or
paraclinical findings to define a specific neurological disease
at the time of sampling (CSF negative for oligoclonal bands,
normal blood brain barrier function, and normal cell count);
(4) inflammatory CNS disease subdivided into (4.1) SA/UA
(n = 10); and (4.2) PBI (n = 9); and (5) neurodegenerative
diseases made up of (5.1) AD and PD (n = 9); and (5.2)
ALS (n = 11). The Table shown in Online Resource 1 sum-
marises patient information.
Lipid Extraction and LC–MS
Non-esterified sterols in plasma were assayed by LC–MS
exploiting enzyme-assisted derivatisation utilising the Girard P
(GP) reagent as illustrated in the Fig. in Online Resource 2. The
method is fully described in [22]. For CSF analysis, the only
modificationsmade to the published protocol for plasmawere that
the volume of CSF used was 250 μL, while that for plasma was
100μL; the concentrations of internal standardswere 16 ng/mLof
24R/S-[25,26,26,26,27,27,27-2H7]hydroxycholesterol, 1.6 ng/mL
of 7α,25-[26,26,26,27,27,27-2H6]dihydroxycholesterol, 16 ng/
mL of 22R-[25,26,26,26,27,27,27-2H7]hydroxylcholest-4-en-3-
one and 16 μg/mL of [25,26,26,26,27,27,27-2H7]cholesterol.
The size of the final C18 column used for CSF was 50 mg while
that used for plasmawas 200mg. Exact details are given inOnline
Resource 3.
Statistical Analysis
An ANOVA test was run for each sterol on linear and
logarithmic scales. The log scale used a transformation
log2(+1) to avoid issues with zero and small numbers.
Uni-variant t tests were performed against the CP group,
*P < 0.05; **P < 0.01. Concentrations given in the text are
mean ± standard deviation (SD). The boxplots in Figs. 1
and 2 and the Figs. in Online Resources 4 and 5 were
generated with default parameters in R version 3.02. The
bottom and top of the central box are the first and third
quartiles, and the band inside the box is the median. The
whiskers extend to the most extreme data points which are
no more than 1.5 times the range between the first and
third quartile distant from the box. Points beyond that are
plotted individually. Pair-wise correlations between CSF or
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plasma levels and specific analyte were performed by R
version 3.02. P values for the significance of the correla-
tions are listed in the Tables in Online Resources 6 and 7,
respectively. The P values that are below 0.05/((21*20)/
2) = 0.000238 for CSF and below 0.05/((22*21)/
2) = 0.000216 for plasma are highlighted in the Online
Resource Tables, these are significant after a Bonferronni
correction at 5 %.
The volcano plots of statistical significance (P values)
against log2 fold change between RRMS and CP shown
in Figs. 1e and 2e, demonstrating the most significantly
differentially regulated metabolites, were generated with
TIBCO Spotfire (TIBCO Software) using log2(+1) transfor-
mation. The t test was made using the modification by
Welch that accommodates for different variances in the
two groups.
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Fig. 1 Effect of CNS disease on
sterol concentrations in plasma.
Box and whiskers plots showing
the concentrations (ng/mL) of a
24S–HC, b 25-HC, c (25R)26-
HC, and d 7αH,3O–CA in
plasma from CIS (n = 16), RRMS
(n = 17), CP (n = 18), SA/UA
(n = 10), PBI (n = 9), AD/PD
(n = 9) and ALS (n = 11) patients.
Uni-variant t tests were performed
against the CP group, *P < 0.05;
**P < 0.01. e Volcano plot for
plasma data showing the P value
versus base2 logarithm of fold
change for the RRMS group
against CP
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Results
Plasma
Shown in Fig. 1a–d and in the Fig. in Online Resource 4 are
box and whisker plots showing the concentrations of non-
esterified oxysterols, 25-hydroxyvitamin D3 (25-D3),
cholestenoic and cholenoic acids in plasma. Table 1 lists the
sterols analysed and the Table in Online Resource 8 gives the
measured concentrations for each patient group. In the RRMS
samples, the concentration of 25-hydroxycholesterol (25-HC)
is reduced significantly compared to CP (1.19 ± 0.26 ng/mL
cf. 1.54 ± 0.42 ng/mL, mean ± SD, P < 0.01). We also see a
reduction in the concentration of (25R)26-hydroxycholesterol
((25R)26-HC, 22.63 ± 5.03 ng/mL cf. 27.97 ± 7.89 ng/mL,
P < 0.05) and 7α-hydroxy-3-oxocholest-4-enoic acid
(b)
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Fig. 2 Effect of CNS disease on
sterol concentrations in CSF. Box
and whiskers plots showing the
concentrations of a cholesterol, b
(25R)26-HC, c 3β-HCA and d
7αH,3O-CA in CSF from CIS
(n = 16), RRMS (n = 17), CP
(n = 18), SA/UA (n = 10), PBI
(n = 9), AD/PD (n = 9) and ALS
(n = 11) patients. Cholesterol
concentration is in microgram per
milliliter other analyte
concentrations are in nanogram
per milliliter. To facilitate
visualisation, the y-axis is on a
log2 scale. Uni-variant t tests
were performed against the CP
group, *P < 0.05; **P < 0.01. e
Volcano plot for CSF data
showing the P value versus base2
logarithm of fold change for the
RRMS group against CP
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(7αH,3O-CA, 50.60 ± 13.33 ng/mL cf. 66.88 ± 26.93 ng/ml
P < 0.05) in RRMS patients. It is important to note that 25-HC
is generated by macrophages [7, 9, 23], while the latter two
compounds are synthesised by multiple different cell
types, making their exact origin in plasma difficult to assess
[24]. The levels of the 25-HC metabolites 7α,25-
d ihydroxycholes te ro l (7α ,25-d iHC) and 7α ,25-
dihydroxycholest-4-en-3-one (7α,25-diHCO) in RRMS plas-
ma do not differ from CP values (0.22 ± 0.08 ng/mL and
1.06 ± 0.33 ng/mL, respectively, Fig. 3). This data suggests
that the fall in 25-HC concentration in RRMS patients is a
consequence of reduced production of 25-HC arising from
either reduced transcription/translation of CH25H or reduced
activity of the enzyme and that RRMS patients have a reduced
capacity to produce 25-HC.
In agreement with some, but not all, earlier studies, the
level of 24S-hydroxycholesterol (24S-HC) is reduced in plas-
ma from the group of patients with either AD or PD compared
to CP (10.51 ± 2.18 ng/mL cf. 14.99 ± 4.57 ng/mL, P < 0.01)
[25, 26]. The level of 25-HC is also reduced in plasma of AD/
PD patients (1.26 ± 0.28 ng/mL, P < 0.05), as it is in patients
diagnosed with PBI (1.28 ± 0.21 ng/mL, P < 0.05), compared
to CP (1.54 ± 0.42 ng/mL).
CSF
It is generally considered that in healthy individuals CSF
levels of (25R)26-HC correlate with levels of this oxysterol
in the circulation [27]. However, this is not necessarily the
case with (25R)26-HC in CSF from patients with neurodegen-
erative diseases [28]. In our study, we find patients
with RRMS, in contrast to our observations in plasma,
show an increase in the concentration of (25R)26-HC in
CSF (0.14 ± 0.07 ng/mL, P < 0.05) compared to CP
(0.10 ± 0.03 ng/mL, Fig. 2, (see also Online Resources 5
and 9). (25R)26-HC can be metabolised in the CNS to
Table 1 Oxysterols, cholestenoic and cholenoic acids and vitamin D3 metabolites analysed by LC–MS in the present study. Concentrations measured
in plasma and CSF are given in Online Resources 8 and 9, respectively
Sterol systematic name (common name) Lipid maps ID Abbreviation Code
9,10-Secocholesta-5Z,7E,10-trien-3β,25-diol (25-Hydroxyvitamin D3) LMST03020246 25-D3 C_1
Cholest-5-en-3β-ol (cholesterol) LMST01010001 C C_2
Cholest-4-ene-3β,6-diol or Cholest-5-ene-3β,6-diol (6-hydroxycholesterol) – 6-HC C_3
Cholest-5-ene-3β,7α-diol (7α-hydroxycholesterol) LMST01010013 7α-HC C_4
7α-Hydroxycholest-4-en-3-one LMST04030123 7α-HCO C_5
Cholest-5-ene-3β,7β-diol (7β-hydroxycholesterol) LMST01010047 7β-HC C_6
3β-Hydroxycholest-5-en-7-one (7-oxocholesterol) LMST01010049 7O-C C_7
Cholest-5-ene-3β,24S-diol (24S-hydroxycholesterol) LMST01010019 24S-HC C_8
Cholest-5-ene-3β,25-diol (25-hydroxycholesterol) LMST01010018 25-HC C_9
Cholest-5-ene-3β,(25R)26-diol ((25R)26-hydroxycholesterol) LMST01010088 (25R)26-HC C_10
Cholest-5-ene-3β,7α,25-triol (7α,25-Dihydroxycholesterol) LMST04030166 7α,25-diHC C_11
7α,25-Dihydroxycholest-4-en-3-one LMST04030107 7α,25-diHCO C_12
Cholest-5-ene-3β,7α,(25R)26-triol (7α,(25R)26-dihydroxycholesterol) LMST04030081 7α,(25R)26-diHC C_13
7α,(25R)26-Dihydroxycholest-4-en-3-one LMST04030157 7α,(25R)26-diHCO C_14
3β-Hydroxycholest-5-enoic acid LMST04030072 3β-HCA C_15
3-Oxocholest-4-enoic acid LMST04030217 3O-CA C_16
3β,7β-Dihydroxycholest-5-enoic acid – 3β,7β-diHCA C_17
3β,7α-Dihydroxycholest-5-enoic acid LMST04030148 3β,7α-diHCA C_18
7α-Hydroxy-3-oxocholest-4-enoic acid LMST04030149 7αH,3O-CA C_19
7α,x-Dihydroxy-3-oxocholest-4-enoic acid – 7α,x-diH,3O-CA C_20
7α,y-Dihydroxy-3-oxocholest-4-enoic acid – 7α,y-diH,3O-CA C_21
7α-Hydroxy-3,24-bisoxocholest-4-enoic acid – 7αH,3,24-diO-CA C_22
7α-Hydroxy-26-nor-cholest-4-ene-3,24-dione – 7αH,26-nor-C-3,24-diO C_23
3β-Hydroxychol-5-enoic acid LMST04010201 3βH-Δ5-BA C_24
3β,7α-Dihydroxychol-5-enoic acid LMST04010217 3β,7α-diH-Δ5-BA C_25
7α-Hydroxy-3-oxochol-4-enoic acid LMST04010239 7αH,3O-Δ4-BA C_26
Note that we use the systematic nomenclature where addition of a hydroxy group to the terminal side chain of cholesterol leading to R stereochemistry at
C-25 gives the compound (25R)26-hydroxycholesterol. In much of the literature, this compound is known by the non-systematic name 27-
hydroxycholesterol
Mol Neurobiol
7αH,3O-CA (Fig. 4) [29, 30]. We find that the concentration
of this acid is elevated in RRMS CSF (27.59 ± 12.93 ng/mL,
P < 0.01) compared to CP (17.40 ± 4.63 ng/mL), as is the level
of its precursor 3β-hydroxycholest-5-enoic acid (3β-HCA,
1.52 ± 0.85 ng/mL cf. 0.96 ± 0.42,P < 0.05). The intermediary
metabolite between these two acids, 3β,7α-dihydroxycholest-
5-enoic acid (3β,7α-diHCA), is also elevated (3.71 ± 4.07 ng/
mL cf. 2.12 ± 1.65 ng/mL) but not to significance. MS is a
demyelinating disease and it likely that cholesterol is released
in the CNS is metabolised through (25R)26-HC and 3β-HCA
to 7αH,3O-CA, although the actual concentration of non-
esterified cholesterol in CSF does not differ from controls
(1.24 ± 0.33 μg/mL). 3β,7β-Dihydroxycholest-5-enoic acid
(3β,7β-diHCA) which may be a metabolic product of 3β-
HCA, 3β,7α-diHCA or 7-oxocholesterol (7O-C) is also ele-
vated in CSF from RRMS patients (0.62 ± 0.35 ng/mL cf.
0.40 ± 0.19 ng/mL, P < 0.05).
The CSF from the ALS group shows differences in choles-
terol metabolite concentrations compared to controls and also
in the concentration of cholesterol itself (1.66 ± 0.36 μg/mL
cf. 1.24 ± 0.33 ng/mL, P < 0.01). The concentration of
7α,(25R)26-dihydroxycholest-4-en-3-one (7α,(25R)26-
diHCO, 0.03 ± 0.01 ng/mL, cf. 0.02 ± 0.01 ng/mL,
P < 0.01) is increased as is its downstream metabolite
7αH,3O-CA, al though not qui te to s ignif icance
(24.45 ± 11.16 ng/mL, cf. 17.40 ± 4.63 ng/mL, P = 0.07).
Other neurodegenerative diseases including AD and PD are
also believed to result in increased cholesterol release in brain
as neurons die [28]. Björkhem and colleagues have found that
patients with PD or AD can have higher CSF levels of
(25R)26-HC than the controls [28, 31, 32]. We find increased
concentrations of metabolites of (25R)26-HC but not of the
oxysterol itself i.e. concentrations of 3β-HCA (1.57 ± 0.55 ng/
mL cf. 0.96 ± 0.42 ng/mL, P < 0.05), 7αH,3O-CA
(25.53 ± 9.52 ng/mL cf. 17.40 ± 4.63 ng/mL, P < 0.05) and
3β,7β-diHCA (0.64 ± 0.16 ng/mL, cf. 0.40 ± 0.19 ng/mL,
P < 0.01) are elevated in this disease group.
Patients diagnosed with PBI show an increase in concen-
tration of 7α,(25R)26-diHCO (0.05 ± 0.03 ng/mL cf.
0.02 ± 0.01 ng/mL, P < 0.05) in CSF while those diagnosed
with SA/UA show increased concentrations of (25R)26-HC
(0.30 ± 0.26 ng/mL cf. 0.10 ± 0.03 ng/mL, P < 0.05),
7α,(25R)26-dihydroxycholesterol (7α,(25R)26-diHC,
0.01 ± 0.01 ng/mL cf. 0.00 ± 0.00 ng/mL, P < 0.05) and
7α,(25R)26-diHCO (0.04 ± 0.02 ng/mL cf. 0.02 ± 0.01 ng/
mL, P = 0.01).
The limit of quantification of our analytical method in CSF
for most analytes is 0.01 ng/mL (10:1, signal to noise); how-
ever, for 25-HC, it is somewhat higher at 0.03 ng/mL, al-
though detection can be made at 0.01 ng/mL. Only in the
patient group of SA/UA (0.06 ± 0.04 ng/mL, cf.
0.03 ± 0.02 ng/mL, P < 0.05) did any of the disease states
show any statistical differences in the level of 25-HC in CSF;
this is also true for the 25-HC metabolite 7α,25-diHCO
(0.07 ± 0.03 ng/mL cf. 0.04 ± 0.02 ng/mL, P < 0.05)
(Fig. 3). The level of non-esterified cholesterol in control
CSF is 1.24 ± 0.33 μg/mL. It is found to be elevated in the
PBI group (3.44 ± 2.05 μg/mL P < 0.05).
Discussion
25-HC Is Reduced in RRMS Plasma
In the current study, we have measured the levels of non-
esterified sterols, oxysterols, 25-D3 and of cholestenoic and
cholenoic acids in plasma and CSF of patients with MS,
neurodegenerative and inflammatory CNS disease. We find
that the level of 25-HC is significantly changed (P < 0.01) in
plasma from patients with RRMS, falling from 1.54 ± 0.42 ng/
mL in CP to 1.19 ± 0.26 ng/mL in RRMS plasma (Figs. 1b, e
and 3). This suggests reduced transcription/translation of the
gene CH25H in macrophages, reduced activity of the CH25H
enzyme, or alternatively, enhanced clearance or metabolism of
25-HC in RRMS patients. The latter possibility is unlikely as
there was no increase in concentration of downstream metab-
olites in plasma. 25-HC levels were also reduced, but to a
lesser extent (P < 0.05), in plasma from patients with PBI
and AD or PD. Non-esterified oxysterols are present in CSF
at pg/mL levels [21], and in control subjects 25-HC is at our
limit of quantification (0.03 ng/mL) and was not found to
change in any of the patient groups except those with SA/
UA where the level increased to 0.06 ± 0.04 ng/mL
(P < 0.05). The plasma data for RRMS patients, indicating a
reduced capacity of macrophages to synthesise 25-HC, is in-
line with the recent study by Reboldi et al. which shows that in
mouse macrophages 25-HC is a mediator of negative feed-
back towards interleukin 1 (IL-1) family cytokine production
and inflammasome activity, through binding to INSIG
(insulin-induced gene) and antagonising the sterol response
element-binding protein-2 (SREBP-2) driven mevalonate
pathway, thereby, reducing Il1b transcription and repressing
IL-1-activating inflammasomes [33]. Thus, reduced amounts
of 25-HC lead to less negative feedback towards IL-1 family
cytokine production in the macrophage, with the consequent
enhancement of inflammation. In keeping with these actions
of 25-HC, Ch25h knockout mice show exacerbated experi-
mental autoimmune encephalomyelitis (EAE), an IL-17-
driven inflammatory disease model of MS, and increased sus-
ceptibility to septic shock. Ch25h-deficient macrophages pro-
duce more proinflammatory IL-17A+ T cells following lipo-
polysaccharide (LPS) stimulation and cytokines that cooper-
ate with transforming growth factor-β (TGFβ) to induce Th17
cells include IL-1β. Notably, after LPS stimulation Ch25h-
deficient macrophages overproduce Il1b [33].
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The mechanism of action by which reduced SREBP pro-
cessing correlates with a reduction in Il1b transcription is not
known. Reboldi et al. suggested that this may be through
reducing the cellular content of sterols generated via the
mevalonate pathway [33]. The results of Reboldi et al. are in
contrast to those of Chalmin et al. who reported that inactiva-
tion of the Ch25h gene significantly attenuates EAE by limit-
ing trafficking of pathogenic CD4+ T lymphocyte to the CNS
[34]. Clearly, morework is needed to reconcile these divergent
results in the literature. Although (25R)26-HC and 7αH,3O-
CAwere, like 25-HC, also found to be reduced (P < 0.05) in
RRMS plasma (Fig. 1), the latter is not known to bind to
INSIG, while neither sterol is formed by IFN-activated mac-
rophages to any significant extent [8]. In contrast, 25-HC is
formed by macrophages in response to IFN [7, 9, 35] and
macrophages are important effector cells involved in the path-
ogenesis of demyelination in MS. 25-HC is also an agonist to
the LXRs [36], as is (25R)26-HC but to a lesser extent and not
at all in neuronal cells [21]. Besides being regulators of lipid
metabolism, LXRs have also been found to modulate immune
and inflammatory responses in macrophages [37]. Thus, re-
duced LXR activation, as a consequence of diminished 25-
HC, may also explain an enhanced inflammatory response in
RRMS. The involvement of LXR in the aetiology of MS is
further supported by the recent report byMeffre et al. showing
that LXRs are involved in the myelination and remyelination
processes in oligodendrocytes [38]. In fact, LXRα or LXRβ
when activated by 25-HC stimulates myelin gene expression
at the promotor, mRNA and protein levels, directly implicat-
ing LXRs in the transcriptional control of myelin gene expres-
sion [38]. In addition, Wang et al. have found an LXRα
mutation, in two multi-incident families presenting with
severe and progressive MS disease, that disrupts LXRα
heterodimerisation and transcriptional activation of target
genes, further linking LXR and its agonists with MS patho-
genesis [39]. In summary, a reduced capacity of macrophages
to generated 25-HC may result in enhanced activity of the
mevalonate pathway leading to over production of Il1b, and
to reduced LXR activation which will both lead to enhanced
inflammatory activity of macrophages recruited to the CNS in
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MS. It might be expected that similar to the situation in plas-
ma, 25-HC concentrations are reduced in CSF from RRMS
patients; however, 25-HC concentrations in control and
RRMS patients were near the limit of quantification making
statistical evaluation difficult.
Demyelination Leads to Activation of Bile Acid
Biosynthesis
In contrast to plasma, there is a significant elevation in
(25R)26-HC (P < 0.05) and of its metabolites 3β-HCA
(P < 0.05) and 7αH,3O-CA (P < 0.01) in CSF of RRMS
patients (Fig. 2). These cholesterol metabolites represent early
members of the “acidic pathway” of bile acid biosynthesis
[40] which is known to be operative in the CNS [29, 30]. A
latter member of this pathway, 7α-hydroxy-3,24-bis-
oxocholest-4-enoic acid (7αH,3,24-diO-CA), formed in the
peroxisome as a thioester is also found to be elevated in
RRMS CSF (Fig. 4). MS is a demyelinating disease with the
consequent release of non-esterified cholesterol in the CNS.
Cholesterol is metabolised in the CNS in astrocytes through
cytochrome P450 (CYP) 27A1 catalysed oxidation to
(25R)26-HC and subsequently to 3β-HCA and then on to
3β,7α-diHCA and 7αH,3O-CA by the consecutive action of
CYP7B1 and hydroxysteroid dehydrogenase (HSD) 3B7 en-
zymes (Fig. 4) [41]. An increase in the availability in CNS of
non-esterified cholesterol, the primary CYP27A1 substrate, is
the likely explanation for the elevated activity of this pathway.
Patients with CIS, which isMS resulting from a single episode
of demyelination in one area of the CNS, also show an in-
crease in the CYP27A1 product 3β-HCA (P < 0.05) but not
its downstream metabolites. Interestingly, both 3β-HCA and
3β,7β-diHCA have been shown to be neurotoxic [21].
Patients with neurodegenerative disease including AD and
PD, or ALS also show an elevation in the metabolites of the
“acidic pathway” in CSF. The cholesterol metabolites 3β-
HCA (P < 0.05) and 7αH,3O–CA (P < 0.01) of the “acidic
pathway” are elevated in the AD and PD group, while in the
ALS group 7α,(25R)26-diHCO (P < 0.01) is increased
(Fig. 4). There are very few other studies of cholestenoic acids
in CSF; however, Saeed et al. found that levels of 7αH,3O-
CAwere similar in AD patients and controls [42]. Brown et al.
have found that CYP27A1 expression increases in oligoden-
drocytes in AD; this may provide an additional route to 3β-
HCA from cholesterol released by dying neurons in this dis-
ease [43].
Patients with inflammatory CNS disease include those di-
agnosed with SA/UA and those diagnosed with PBI. The pa-
tients with SA/UA show elevated levels of 25-HC in CSF
(P < 0.05, Fig. 3) but not in the circulation. Notably, the
metabolite of 25-HC, 7α,25-diHCO is also elevated in CSF
of these patients (P < 0.05) as are (25R)26-HC (P < 0.05),
7α,(25R)26-diHC (P = 0.05) and 7α,(25R)26-diHCO
(P = 0.01). When plasma was analysed from these patients,
none of the metabolites showed statistical differences com-
pared to controls except 7α,(25R)26-diHCO, which unlike
the situation in CSF was reduced in concentration in plasma
(P < 0.05). Little is known of the regulation of enzymes of the
acidic pathway of bile acid biosynthesis [44]. However, the
drive for an increased flux through the “acidic pathway” may
be a consequence of increased availability of non-esterified
cholesterol. In fact, the absence of a change in non-esterified
cholesterol levels in CSF in all disease groups, except those
with PBI or ALS, highlights its tight regulation in CNS. The
increased CSF concentrations of metabolites of the “acidic
pathway” of bile acid biosynthesis indicate that this pathway
represents a salvage route for removal of excess cholesterol in
CNS disease which may be defective or overstretched in
ALS and PBI. The explanation for the increase in 25-HC in
CSF of SA/UA patients may be an up-regulation of the
IFN-stimulated gene CH25H in macrophages of the
inflamed CNS.
Pair-Wise Correlations between Sterols
It is of interest to study pair-wise correlations between CSF
concentrations and specific sterol analytes which are arranged
in metabolic order in Fig. 5. We have omitted the inflamma-
tory CNS disease group from Fig. 5 as many correlations are
driven by this group (see Online Resource 6 for P values for
the significance of correlation (A) excluding and (B) including
the inflammatory CNS disease group). As might be expected
(25R)26-HC is highly correlated with 7α,(25R)26-diHC and
3β-HCA corresponding to the first metabolites of the two
branches of the “acidic pathway” of bile acid biosynthesis
(Fig. 4). (25R)26-HC also correlates with 7α,(25R)26-
diHCO the downstream metabolite of 7α,(25R)26-diHC and
with 3β,7α-diHCA and 3β,7β-diHCA, downstream metabo-
lites of 3β-HCA, but to a lesser extent. Concentrations of
(25R)26-HC also correlate with 24S-HC, presumably as both
have cholesterol as their precursor. Both 24S-HC and
(25R)26-HC correlate strongly with cholesterol. 25-HC also
correlates with (25R)26-HC but less strongly than 24S-HC.
7α,(25R)26-diHC correlates strongly with its downstream
metabolite 3β,7α-diHCA, while 7α,(25R)26-diHCO corre-
lates most strongly with 7α,25-diHCO, both products of
HSD3B7 metabolism. 3β-HCA correlates very strongly with
3β,7β-diHCA and less strongly with 7αH,3O-CA and
3β,7α-diHCA. 3β,7α-diHCA correlates most strongly with
7α,(25R)26-diHC and 3β,7β-diHCA. This data suggest that
the 7α,(25R)26-diHC branch provides the primary route to
3β,7α-diHCA in CNS. 7αH,3O-CA correlates with
7αH,3,24-diO-CA and the ultimate metabolite found in
CSF, 7α-hydroxy-3-oxochol-4-enoic acid (7αH,3O-Δ4-BA).
A fascinating feature of the pair-wise correlations is the tight
cluster indicated by the “red box” incorporating 7αH,3O-CA,
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two dihydroxy-3-oxocholest-4-enoic acid isomers (7α,x-
diH,3O-CA and 7α,y-diH,3O–CA) and 7αH,3,24-diO-CA.
We do not have an authentic standard for the latter compound
whose identification is based on exact mass, retention time
and multistage fragmentation (MSn) spectrum and the location
of the hydroxy groups on the two dihydroxy-3-oxocholest-4-
enoic acid isomers is unclear. In both isomers, one hydroxy
group is located at the 7α position while the second hydroxy
group is most likely on the side chain. The pair-wise correla-
tions between successive members of the “acidic pathway”
provide strong evidence for the activity of this pathway
in the CNS. The absence of correlations with 7α-
hydroxycholesterol (7α-HC) confirms that the “neutral path-
way” of bile acid biosynthesis is not operative in the CNS. The
rate limiting enzyme of this pathway, CYP7A1, is liver spe-
cific [40]. The correlations between specific oxysterols and
individual samples, including the inflammatory CNS disease
group, are shown in the Fig. in Online Resource 10. As is
evident from the dendrogram, the five acids 7αH,3O-Δ4-
BA, 7αH,3,24-diO-CA; 7αH,3O-CA; 7α,x-diH,3O-CA; and
7α,y-diH,3O-CA cluster together, as do 3β-HCA, (25R)26-
HC, 3β,7β-diHCA, 3β,7α-diHCA and 7α,(25R)26-diHC.
The clustering patterns evident in the dendrogram in Online
Resource 10 provide further evidence for an active bile acid
biosynthesis pathway in CNS (Fig. 4). The dendrogram
groups together 7O–C, 6-hydroxycholeserol (6-HC) and 7α-
HC, these are all potential autoxidation products (see Online
Resource 3).
While the metabolite correlations in CSF are dominated
by the “acidic pathway” of bile acid biosynthesis, the cor-
relations in plasma are reflective of both the “acidic path-
way” and of the “neutral pathway” starting with 7α-HC
followed by 7α-hydroxycholest-4-en-3-one (7α-HCO,
Fig. 4) which are strongly correlated (Online Resource 11,
see Online Resource 7 for P values for the significance of
correlation). As expected from the pathway outlined in
Fig. 4, 7α-HCO correlates with 7α,(25R)26-diHCO,
7αH,3OCA and 7αH,3O-Δ4-BA, while (25R)26-HC corre-
lates with 3β-HCA and 7αH,3O-CA. Unsurprisingly, 3β-
HCA correlates strongly with 3β,7α-diHCA, while
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7αH,3O-CA correlates strongly with 7αH,3O-Δ4-BA. As
evident from the dendrogram in the Fig. in Online
Resources 12, 25-HC clusters most strongly with 24S-HC
and both cluster with their precursor cholesterol, while
7α,25-diHC and 7α,(25R)26-diHC cluster together as do
their HSD3B7 products 7α,25-diHCO and 7α,(25R)26-
diHCO. 7α,25-diHC and 7α,(25R)26-diHC share CYP7B1
as the ultimate enzyme in their biosynthesis.
In summary, we have analysed plasma and CSF from pa-
tients with CIS and RRMS as well as from patients with in-
flammatory CNS disease, neurodegenerative disease and
symptomatic control patients. In plasma we find that the con-
centration of 25-HC in RRMS patients is significantly lower
than in controls. This is consistent with the recent report of
Reboldi et al. that lower concentrations of 25-HC in Ch25h-/-
mouse plasma results in reduced negative feedback by 25-HC
on IL-1 family cytokine production and an exacerbated EAE,
a rodent paradigm of MS [33]. In CSF, we find that the dom-
inating cholesterol metabolites reflect the “acidic pathway” of
bile acid biosynthesis and the elevated levels of these metab-
olites in CNS disease is likely to reflect cholesterol release as a
result of demyelination or neuron death.
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